Boxing’s Elite and Researchers Unite to Fight COVID-19
AVEX IMPACT Announces Strategic Partnership with American Dream Present, Sterling Promotions and J3G Global.

Las Vegas, NV, July 09, 2020 (GLOBE NEWSWIRE) — AVEX IMPACT from AEVOLVE AG announces strategic partnership with American Dream Present, Sterling Promotions and J3G Global, jointly developing a new platform that combines premium entertainment and world-class boxing events managed by industry icons with novel financing models that leverage AEVOLVE’s technology portfolio and digital assets. The objective is to create new opportunities that enhance financing for solutions that can be leveraged by non-profits, philanthropic organizations, and medical research initiatives.

Million-Dollar Drugs: Encouraging News for Patients with Rare Diseases, But at What Cost?

In recent years, there has been some good news for many of the 30 million people in the U.S. diagnosed with a rare disease, in the form of long-awaited treatment for a number of specific conditions — but this progress has come at a staggering cost for these prescription medications. Fortunately, a new company focusing on life sciences — AEVOLVE AG — has a plan to support medical research that will benefit millions of others with rare diseases, without the alarming costs that are currently associated with drugs of this kind.

AEVOLVE, AG Partners with MPECT Inc. to Provide Healthcare Innovators with Proactive Global Compliance Support

ATLANTASept. 24, 2019 /PRNewswire/ — AEVOLVE, AG, a new firm using the blockchain investment platform to support innovative medical research announced today that it has established a strategic partnership with MPECT, Inc., a pioneer in the use of Cloud computing, Artificial Intelligence and data analytics to provide those in the healthcare sector with constantly evolving compliance and regulatory information and systems.

New Blockchain Models for Medical Financing: Why Aevolve is at the Forefront

Burdened by declining productivity and innovation, biopharma is seeking new ways of financing its growing needs. According to the Tufts Center for the study of Drug Development (CSDD), the cost to develop a new prescription drug is pegged at $2.6 billion. This marks a 145% increase from 2003 estimates, according to an article republished on Scientific American.